Free Newsletter
SC nominee backed Merck shareholder suit
Free newsletter via e-mail
Tools
Want a pharma connection to President Obama's new Supreme Court nominee Elana Kagan? As U.S. Solicitor General, Kagan backed the shareholders who were suing Merck (NYSE: MRK) over claims that the company misrepresented the safety of Vioxx; Kagan agreed that the investors hadn't waited past the statute of limitations to file the lawsuits. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: